Conexiant’s news site is now MDSpire News. Learn more
Advertisement
NHS-Galleri Linked to Delays
Analysis of England’s multicancer early detection screening trial found modest, temporary diagnostic delays in participating regions, adding to concerns about health system effects and the evidence base for population-level blood-based cancer screening.
The NHS-Galleri trial was associated with increased diagnostic delay rates for certain cancers during its first year. Participation in the trial led to a modest rise in delays, with an estimated 9,591 additional referrals experiencing diagnostic delays.
Background
The NHS-Galleri trial evaluates a blood-based multicancer early detection test that aims to identify multiple cancer types using cell-free DNA. Understanding the impact of such trials on diagnostic timelines is crucial, as delays in cancer diagnosis can affect treatment outcomes. This study highlights the potential unintended consequences of implementing new screening technologies within existing healthcare systems.
Data Highlights
Time Period
Diagnostic Delay Rate (Participating Regions)
Diagnostic Delay Rate (Non-Participating Regions)
First 6 Months
30%
26%
Second 6 Months
Higher by 5 percentage points
N/A
Key Findings
Participation in the NHS-Galleri trial was linked to a 3-percentage-point increase in diagnostic delay rates for certain cancers.
During the first 6 months, diagnostic delay rates increased from 29% to 30% in participating regions.
Average time to diagnostic resolution increased by about 2 days in participating regions.
Approximately 24 additional referrals per 100,000 population for suspected cancers occurred in participating regions during the first 6 months.
The estimated increase in delayed referrals was 9,591 during the first year of the trial.
Clinical Implications
The findings suggest that the implementation of new screening tests like the NHS-Galleri may inadvertently lead to increased diagnostic delays. Clinicians should be aware of potential impacts on referral patterns and diagnostic timelines when integrating new technologies into practice.
Conclusion
The NHS-Galleri trial illustrates the complexities of introducing new cancer screening methods, highlighting the need for careful monitoring of diagnostic processes.
Plasma proteomic models of more than 40 cell types were associated with incident Alzheimer's disease, amyotrophic lateral sclerosis, cancer, and mortality across three large cohorts.
National survey findings suggest many US adults report making health decisions based on social media despite widespread concerns about the accuracy of health information shared to the platforms.
A randomized clinical trial found higher chronic GVHD-free survival and lower rates of serious chronic GVHD compared with standard transplantation in adults with blood cancers.
